Human beta-migrating very low density lipoprotein induces foam cell formation in human mesangial cells

Atherosclerosis
Y AnamiM Shichiri

Abstract

To elucidate the mechanism of foam cell formation in the mesangial region of a kidney observed in a familial type III hyperlipoproteinemic patient presenting with diabetes mellitus and nephrotic syndrome, we have examined, in the present study, the effect of human beta-VLDL (apo E2/E2) on foam cell formation in human mesangial cells, since an increase in beta-VLDL is a characteristic feature of this patient. Human beta-VLDL (apo E2/E2) induced foam cell formation in human mesangial cells. The binding of [125I]LDL to human mesangial cells was inhibited completely by both LDL and beta-VLDL. On the other hand, the binding of [125I]beta-VLDL was completely inhibited by beta-VLDL, but partially by LDL. The LDL receptor, but not the VLDL receptor was down-regulated by accumulation of cholesteryl esters. These results suggest that human beta-VLDL (apo E2/E2)-induced foam cell formation in mesangial cells is mediated through both the LDL receptor pathway and the beta-VLDL specific pathway, in which the VLDL receptor is one of the candidates.

References

Sep 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·H TowbinJ Gordon
Aug 11, 1992·Proceedings of the National Academy of Sciences of the United States of America·D P ViaH A Dresel
Oct 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·S TakahashiT Yamamoto
Feb 1, 1990·Nature·J L Goldstein, M S Brown
Apr 4, 1986·Science·M S Brown, J L Goldstein
Oct 15, 1974·Clinica Chimica Acta; International Journal of Clinical Chemistry·W J Godolphin, R A Stinson
Jan 1, 1969·The Journal of Pathology·I F McKenzie, P Kincaid-Smith
Sep 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·M KriegerD Kingsley
Jan 1, 1983·Methods in Enzymology·J L GoldsteinM S Brown
Aug 1, 1980·Kidney International·H L Sheehan
Aug 29, 1995·Proceedings of the National Academy of Sciences of the United States of America·P K FrykmanJ Herz
May 1, 1994·Atherosclerosis·E F GröneD Seidel
Jul 1, 1993·Atherosclerosis·K SuzakiH Takeda

❮ Previous
Next ❯

Citations

Nov 6, 2010·Diabetologia·T M E DavisUNKNOWN Fenofibrate Intervention and Event Lowering in Diabetes Study investigators
Jul 31, 2002·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Masaaki EtoKohei Kaku
Sep 3, 2014·PloS One·Joseph G S TsunKathryn C B Tan
Apr 7, 2000·Journal of the American Society of Nephrology : JASN·Jaap A JolesJürgen Floege

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.